Mizuho Boosts GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $110.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price target lifted by Mizuho from $96.00 to $110.00 in a research report report published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also issued reports on the company. Morgan Stanley increased their price target on GE HealthCare Technologies from $74.00 to $86.00 and gave the stock an equal weight rating in a report on Monday, February 12th. Argus increased their price target on GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a buy rating in a report on Monday, April 1st. Citigroup raised their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a buy rating in a report on Wednesday, April 3rd. HSBC started coverage on GE HealthCare Technologies in a report on Thursday, February 15th. They issued a buy rating and a $100.00 target price on the stock. Finally, Evercore ISI raised their target price on GE HealthCare Technologies from $93.00 to $100.00 and gave the company an outperform rating in a report on Thursday, April 4th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $95.08.

GE HealthCare Technologies Stock Down 2.2 %

Shares of NASDAQ:GEHC opened at $86.28 on Thursday. The business’s 50 day simple moving average is $88.21 and its two-hundred day simple moving average is $77.29. The firm has a market cap of $39.37 billion, a P/E ratio of 28.57, a PEG ratio of 3.07 and a beta of 0.94. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.83 and a current ratio of 1.05. GE HealthCare Technologies has a 52-week low of $62.35 and a 52-week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.11. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.09 billion. GE HealthCare Technologies had a return on equity of 25.58% and a net margin of 8.02%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 earnings per share. As a group, research analysts forecast that GE HealthCare Technologies will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Friday, April 19th will be given a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. The ex-dividend date is Thursday, April 18th. GE HealthCare Technologies’s payout ratio is 3.97%.

Institutional Trading of GE HealthCare Technologies

A number of institutional investors and hedge funds have recently modified their holdings of GEHC. Barclays PLC purchased a new stake in shares of GE HealthCare Technologies during the second quarter valued at approximately $92,462,000. Thrivent Financial for Lutherans purchased a new stake in shares of GE HealthCare Technologies during the second quarter valued at approximately $1,590,000. MML Investors Services LLC purchased a new stake in shares of GE HealthCare Technologies during the second quarter valued at approximately $929,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of GE HealthCare Technologies during the second quarter valued at approximately $3,474,000. Finally, Tower Research Capital LLC TRC purchased a new stake in GE HealthCare Technologies in the second quarter worth $1,150,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.